Magnetotherapy in patients with malignant tumors receiving immunotherapy

Koneva E.S.; Mochalova A.S.; Suetina M.S.; Sidyakina I.V.; Shapovalenko T.V.; Vasileva E.S.; Butenko A.V.; Shatveryan G.A.; Batukhtina E.V.; Kotenko K.V.

doi:https://doi.org/10.17116/kurort20229904251

Koneva E.S.

Center of Restorative Medicine of the MEDSI group;
Sechenov First Moscow State Medical University

ORCID: 0000-0002-9859-194X

Mochalova A.S.

Group of companies MEDSI

ORCID: 0000-0002-7681-5383

Suetina M.S.

Group of companies MEDSI

Sidyakina I.V.

Group of companies «MEDSI»

ORCID: 0000-0002-0998-9252

Shapovalenko T.V.

Group of companies «MEDSI»

Vasileva E.S.

The first medical and pedagogical center «Lingua Bona»

Butenko A.V.

Petrovsky National Research Centre of Surgery

Shatveryan G.A.

Petrovsky Russian Research Center of Surgery

Batukhtina E.V.

Petrovsky National Research Centre of Surgery

Kotenko K.V.

Russian research center of surgery named after academician B.V. Petrovsky;
The Moscow state medical University named after A.I. Evdokimov of the Ministry of health of Russia

ORCID: 0000-0002-6147-5574

Magnetotherapy in patients with malignant tumors receiving immunotherapy

Authors:

Koneva E.S., Mochalova A.S., Suetina M.S., Sidyakina I.V., Shapovalenko T.V., Vasileva E.S., Butenko A.V., Shatveryan G.A., Batukhtina E.V., Kotenko K.V.

More about the authors

Journal: Problems of Balneology, Physiotherapy and Exercise Therapy. 2022;99(4‑2): 51‑60

DOI: 10.17116/kurort20229904251

Read: 2810 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Koneva ES, Mochalova AS, Suetina MS, et al. . Magnetotherapy in patients with malignant tumors receiving immunotherapy. Problems of Balneology, Physiotherapy and Exercise Therapy. 2022;99(4‑2):51‑60. (In Russ.)
https://doi.org/10.17116/kurort20229904251

Подписка 2026 Вопросы курортологии, физиотерапии и лечебной физической культуры (Problems of Balneology, Physiotherapy and Exercise Therapy)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To analyze the quality of life in patients receiving immunotherapy and overall response rate in case of additional magnetotherapy.

MATERIAL AND METHODS

The study included 3 cohorts of patients (n=48) with various disseminated malignancies (melanoma, lung cancer, kidney cancer) who received immunotherapy. In the study groups, all patients additionally took courses of rehabilitation based on magnetotherapy. In the control cohorts, patients underwent courses of immunotherapy without additional magnetic therapy. Treatment efficacy was assessed according to iRECIST 1.1 criteria. The Russian version of the EORTC QLQ-C30 questionnaire was used to study the quality of life. We analyzed adverse events using the CTCAE 5.0 criteria.

RESULTS

In patients with melanoma, the most common response to systemic treatment was stabilization (41.7% in the study group and 30.8% in the control group). The objective response rate was higher in the study group (33.3% vs. 23.1%). There was also significant improvement in the quality of life after treatment in the study group (by 23.5%). In the control group, the indicator worsened by 4.8%. Overall health improved by 12.8% in the study group and 10.3% in the control group. In patients with lung cancer, response to systemic treatment with stabilization was achieved in 33.3% of patients in the study group and 20% of patients in the control group. The objective response rate was 33.3% and 20%, respectively. Analysis of the study group revealed improvement of overall health by 9.6% and overall quality of life by 38.6%. In the control group, overall health improved by 4.8% and quality of life remained the same. In patients with kidney cancer, the objective response rate was 40% and 42.9%, respectively. Disease stabilization was achieved in 40% and 28.6% of patients, respectively. Overall health improved by 16.7% and 6.3%, overall quality of life – by 19% and 9.1%, respectively.

CONCLUSION

Magnetic therapy during the course of immunotherapy improved the overall quality of life and reduced severity of adverse events. Further study of magnetotherapy as an accompanying rehabilitation technique is required.

Keywords:

immunotherapy

magnetotherapy

oncology

rehabilitation

Authors:

Koneva E.S.

Center of Restorative Medicine of the MEDSI group;
Sechenov First Moscow State Medical University

ORCID: 0000-0002-9859-194X

Mochalova A.S.

Group of companies MEDSI

ORCID: 0000-0002-7681-5383

Suetina M.S.

Group of companies MEDSI

Sidyakina I.V.

Group of companies «MEDSI»

ORCID: 0000-0002-0998-9252

Shapovalenko T.V.

Group of companies «MEDSI»

Vasileva E.S.

The first medical and pedagogical center «Lingua Bona»

Butenko A.V.

Petrovsky National Research Centre of Surgery

Shatveryan G.A.

Petrovsky Russian Research Center of Surgery

Batukhtina E.V.

Petrovsky National Research Centre of Surgery

Kotenko K.V.

Russian research center of surgery named after academician B.V. Petrovsky;
The Moscow state medical University named after A.I. Evdokimov of the Ministry of health of Russia

ORCID: 0000-0002-6147-5574

Received:

07.06.2022

Accepted:

10.08.2022

Close metadata

References:

Grippin AJ, Sayour EJ, Mitchell DA. Translational nanoparticle engineering for cancer vaccines. Onco Immunology. 2017;6:e1290036.
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651-668.
Puzanov I, Diab A, Abdallah K, Bingham CO III, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS. Society for immunotherapy of cancer toxicity management working: managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity management working group. J Immunother Cancer. 2017;5:95. https://doi.org/10.1186/s40425-017-0300-z
Wang S, Sun Z, Hou Y. Engineering nanoparticles toward the modulation of emerging cancer immunotherapy. Adv Healthc Mater. 2021;10:2000845.
Burmistrov AL, Myasnikov IG. Uchebno-metodicheskoe posobie po primeneniyu magnitoterapevticheskoj ustanovki EOL (Magnitoturbotron). Pod red. Troshina V.D. Nizhnij Novgorod; 2003. (In Russ.).
Epifanov VA, Epifanov AV, Korchazhkina NB. Physical therapy: tutorial guide. Epifanov VA, Epifanov AV, Korchazhkina NB. Physical therapy: tutorial guide. Moscow: GEOTAR-Media; 2020.
Abuseva GR, Antipenko PV, Arkov VV, Badtieva VA, Baranovskij AYu, Baturina LA, Bogacheva EL, Bolotova NV, Bulan’kov YuI, Bykova OV, Vahova EL, Voloshina NI, Gerasimova GV, Demchenko EA, Didur MD, Drakon AK, Ezhov VV, Epifanov VA, Efimenko NV, Zhevago NA, Zaripova TN, Ivanova ES, Kajsinova AS, Karpova TN, Karu TJ, Klyuchareva SV, Knyazeva TA, Kovlen DV, Kolchev AI, Kondrina EF, Korchazhkina NB, Kotenko KV, Kurganskaya IG, Kurdybajlo SF, Kuyanceva LV, Lebedev VP, Lyubachev AV, Lobzin YuV, Lyan NA, Malikov AYa, Mahotkina NN, Medalieva RH, Merzlikin AV, Minenko IA, Miryutova NF, Mihajlov AV, Mihajlova AA, Novikova EV, Obrezan AG, Osipov YuS, Petrova MS, Pirogova SV, Podberezkina LA, Podgornaya OV, Popova OF, Portnov VV, Ruseva SV, Svincov AA, Skoromec AA, Stepanenko OV, Stranadko EF, Strukova NV, Subbotin FA, Tal’kovskij EM, Tokareva DV, Tolmachev SV, Ulashchik VS, Havinson VH, Han MA, Chervinskaya AV, Cherkashina IV, Shamrej VK, Shiman AG, Shoferova SD, Ponomarenko GN. Physical and rehabilitation medicine: national leadership. Interregional Scientific Society of Physical and Rehabilitation Medicine, Association of Medical Societies for Quality. Moscow: GEOTAR-Media; 2020. (In Russ.).
Epifanov VA, Korchazhkina NB. Mediko-social’naya reabilitaciya pacientov s razlichnoj patologiej: V 2-h chastyah. Moskva: GEOTAR-Media; 2019. (In Russ.).
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. https://doi.org/10.1016/j.ejca.2008.10.026
U.S. department of health and human services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. US: U.S. department of health and human services; 2017. Accessed August 16, 2022. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
EORTC QLQ-C30 (version 3). Accessed August 16, 2022. https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf